| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, ... The Lancet 389 (10064), 56-66, 2017 | 3657 | 2017 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 897 | 2021 |
| Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma JC Wu, YH Huang, GY Chau, CW Su, CR Lai, PC Lee, TI Huo, IJ Sheen, ... Journal of hepatology 51 (5), 890-897, 2009 | 499 | 2009 |
| Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B YH Huang, LT Hsiao, YC Hong, TJ Chiou, YB Yu, JP Gau, CY Liu, ... Journal of Clinical Oncology 31 (22), 2765-2772, 2013 | 373 | 2013 |
| Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial RS Finn, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, O Yokosuka, ... Journal of hepatology 69 (2), 353-358, 2018 | 360 | 2018 |
| Gastrointestinal and liver manifestations in patients with COVID-19 IC Lee, TI Huo, YH Huang Journal of the Chinese Medical Association 83 (6), 521-523, 2020 | 317 | 2020 |
| Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients CW Su, YH Huang, TI Huo, HH Shih, IJ Sheen, SW Chen, PC Lee, ... Gastroenterology 130 (6), 1625-1635, 2006 | 286 | 2006 |
| Prognosis of hepatocellular carcinoma: assessment of eleven staging systems PH Liu, CY Hsu, CY Hsia, YH Lee, CW Su, YH Huang, FY Lee, HC Lin, ... Journal of hepatology 64 (3), 601-608, 2016 | 277 | 2016 |
| Genetic polymorphisms of manganese superoxide dismutase, NAD (P) H: quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury YS Huang, WJ Su, YH Huang, CY Chen, FY Chang, HC Lin, SD Lee Journal of hepatology 47 (1), 128-134, 2007 | 261 | 2007 |
| A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements M Kudo, KH Han, SL Ye, J Zhou, YH Huang, SM Lin, CK Wang, M Ikeda, ... Liver cancer 9 (3), 245-260, 2020 | 243 | 2020 |
| Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients TH Su, TH Hu, CY Chen, YH Huang, WL Chuang, CC Lin, CC Wang, ... Liver International 36 (12), 1755-1764, 2016 | 222 | 2016 |
| Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system CY Hsu, YH Lee, CY Hsia, YH Huang, CW Su, HC Lin, RC Lee, YY Chiou, ... Hepatology 57 (1), 112-119, 2013 | 210 | 2013 |
| Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study CF Tsai, MH Chen, YP Wang, CJ Chu, YH Huang, HC Lin, MC Hou, ... Gastroenterology 152 (1), 134-141, 2017 | 203 | 2017 |
| A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System CY Hsu, YH Huang, CY Hsia, CW Su, HC Lin, CC Loong, YY Chiou, ... Journal of hepatology 53 (1), 108-117, 2010 | 193 | 2010 |
| Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma≤ 2 cm in a propensity score model PH Liu, CY Hsu, CY Hsia, YH Lee, YH Huang, YY Chiou, HC Lin, TI Huo Annals of surgery 263 (3), 538-545, 2016 | 188 | 2016 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative … LT Chen, E Martinelli, AL Cheng, G Pentheroudakis, S Qin, ... Annals of Oncology 31 (3), 334-351, 2020 | 179 | 2020 |
| Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas HH Hung, YY Chiou, CY Hsia, CW Su, YH Chou, JH Chiang, WY Kao, ... Clinical Gastroenterology and Hepatology 9 (1), 79-86, 2011 | 177 | 2011 |
| RESORCE Investigators Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled … J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, ... Lancet 389 (10064), 56-66, 2017 | 173 | 2017 |
| ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era PH Liu, CY Hsu, CY Hsia, YH Lee, YY Chiou, YH Huang, FY Lee, HC Lin, ... Journal of gastroenterology and hepatology 32 (4), 879-886, 2017 | 166 | 2017 |
| Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 164 | 2022 |
Teh-Ia HuoTaipei Veterans General Hospital在 vghtpe.gov.tw 的电子邮件经过验证
